Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a positive outlook with a 25% revenue increase and reduced net loss, despite increased R&D expenses. The company's strategic plan includes self-sustaining revenue projections and a commercial strategy for 2026, suggesting growth potential. However, the call lacked detailed strategic initiatives and operational updates, and highlighted risks in regulatory and market conditions. Overall, the financial performance and optimistic future plans outweigh the risks, leading to a positive sentiment.
Key Financial Performance
Revenue Verastem reported revenue of $12.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was driven by strong sales of their oncology products and expanded market penetration.
Net Loss The company reported a net loss of $8.3 million for Q1 2026, which is an improvement compared to the $10.1 million net loss in Q1 2025. The reduction in net loss was attributed to increased revenue and cost management initiatives.
Research and Development Expenses R&D expenses were $6.2 million for Q1 2026, up 15% year-over-year. The increase was due to ongoing clinical trials and investment in pipeline development.
General and Administrative Expenses G&A expenses were $3.8 million for Q1 2026, a 5% decrease year-over-year. This reduction was due to cost-saving measures implemented by the company.
Cash and Cash Equivalents The company reported cash and cash equivalents of $45 million as of the end of Q1 2026, compared to $50 million at the end of Q1 2025. The decrease was primarily due to increased R&D spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could lead to material differences in actual results.
Regulatory risks: Potential challenges in meeting regulatory requirements or obtaining necessary approvals for products.
Market conditions: Uncertainties in market conditions that could impact the company's performance.
Financial risks: Dependence on non-GAAP financial measures and potential discrepancies in financial reporting.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Andres Maldonado
BTIG LLC
CEO Director
Cantor Fitzgerald
Director Calkins
Director Glen
Division Andres
Division Faisal
Division Jeet
Division Leonid
Division Schmidt
Division Venezia
Division Yuan
Division afternoon
EDT Eric
Eric Schmidt
Faisal Khurshid
Glen Kauffman
Jeet Mukherjee
Khurshid Jefferies
Leonid Timashev
Maldonado HC
Mukherjee BTIG
Officer PM
Oncology statement
PM EDT
Relations Paterson
Timashev RBC
Venezia Alliance
Yuan Zhi
Zhi Riley
risk
VSTM Transcript
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call indicates a positive outlook with a 25% revenue increase and reduced net loss, despite increased R&D expenses. The company's strategic plan includes self-sustaining revenue projections and a commercial strategy for 2026, suggesting growth potential. However, the call lacked detailed strategic initiatives and operational updates, and highlighted risks in regulatory and market conditions. Overall, the financial performance and optimistic future plans outweigh the risks, leading to a positive sentiment.
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings call summary indicates strong revenue growth and a solid financial position, but also highlights increasing losses and expenses. The Q&A reveals concerns about reimbursement and regulatory challenges, although the company is optimistic about future developments. The absence of clear guidance and specifics on certain issues could cause uncertainty. The combination of these factors suggests a neutral sentiment, as positive developments are balanced by potential risks and uncertainties.
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reflects positive sentiment due to early adoption of the new product, a strong financial runway, and strategic plans for clinical trials and market expansion. Despite some uncertainties in patient data and NCCN feedback, the overall outlook is optimistic with potential for label expansion and interest from partners. The positive adoption and feedback from healthcare providers, combined with a solid cash position, suggest a favorable stock price reaction.
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance, positive product development updates, and effective market strategy, with minimal payer pushback and successful reimbursement strategies. The Q&A section reinforced positive sentiment with management's confidence in launch momentum and successful engagement with the healthcare community. Despite some uncertainties in EU approval timelines, the overall outlook is optimistic, with a focus on expansion and minimal financial concerns.
VSTM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
